🟠 Moderate Evidence
Smartphone applications and wearable fitness devices demonstrably increase physical activity levels in patients with established cardiovascular disease, according to a meta-analysis published in the Journal of the American Heart Association. The analysis synthesised data from multiple controlled trials to assess the efficacy of digital monitoring and feedback systems in a population at high risk of recurrent cardiac events.
Key takeaways
- Digital health interventions — smartphone apps, fitness trackers, and wearable sensors — significantly improve physical activity adherence in cardiac patients
- The meta-analysis synthesised evidence from multiple randomised and quasi-randomised trials to establish the effect size of digital monitoring
- Real-time feedback and activity tracking appear to enhance motivation and accountability among patients with diagnosed heart disease
- Integration of digital tools into cardiac rehabilitation programmes may strengthen implementation of evidence-based guidelines for secondary prevention
Study at a Glance
| Source | Journal of the American Heart Association |
| Study type | Meta-analysis of randomised and quasi-randomised controlled trials |
| Population | Adults with diagnosed cardiovascular disease |
| Intervention | Smartphone applications, wearable trackers, and digital activity monitoring devices |
| Primary outcome | Objectively measured or self-reported physical activity levels |
Digital interventions boost activity in heart disease
Effectiveness hierarchy of smartphone apps, wearables, and integrated monitoring systems for increasing physical activity — based on meta-analysis of controlled trials
Source: Journal of the American Heart Association meta-analysis | Georgian Medical Journal News
Digital monitoring bridges the cardiac activity gap
Cardiac rehabilitation guidelines from the American Heart Association and international cardiology societies consistently recommend at least 150 minutes of moderate-intensity aerobic activity per week for patients post-myocardial infarction or with heart failure. However, real-world adherence remains poor, with studies showing that fewer than 30% of eligible patients sustain prescribed activity levels beyond 12 months post-event. The meta-analysis published in the Journal of the American Heart Association examined whether digital tools — which provide continuous monitoring, automated reminders, and personalised feedback — could address this implementation gap.
Wearable devices capture objective step counts, heart rate, and activity duration without requiring active user engagement beyond initial setup. Smartphone applications offer additional functionality: goal-setting interfaces, social comparison features, and integration with existing health records. The combination of objective tracking (via wearables) and motivational scaffolding (via apps) appears to produce stronger behavioural effects than either modality alone, suggesting a synergistic mechanism.
Effect size and clinical relevance
The meta-analysis pooled data across multiple randomised controlled trials to estimate the net effect of digital interventions on activity levels. Across studies, participants assigned to app- and wearable-supported interventions consistently demonstrated increased daily step counts and sustained activity engagement compared to control groups receiving standard cardiac rehabilitation. The consistency of this effect across diverse patient populations and intervention designs suggests robust clinical relevance.
Importantly, the benefit was not limited to highly engaged or digitally literate subgroups. Older adults and those with lower baseline technology familiarity showed comparable activity improvements when interventions included user support and simplified interfaces. This suggests that age and prior device experience need not be barriers to adoption in clinical settings. Integration into existing electronic health record systems further enhances uptake by reducing additional administrative burden on both patients and clinical staff.
Meta-analysis of controlled trials demonstrates that smartphone apps and wearable trackers significantly increase physical activity in patients with cardiovascular disease, with effect sizes persisting across diverse populations and intervention designs.
— Journal of the American Heart Association meta-analysis
Secondary prevention and long-term outcomes
Physical activity is a cornerstone of secondary prevention in cardiovascular disease, reducing rehospitalisation rates, improving ejection fraction recovery in heart failure, and lowering cardiovascular mortality risk. Despite its documented benefits, many patients struggle to maintain prescribed activity levels due to fatigue, dyspnoea, psychological distress, or simply the absence of external structure. Digital tools address these barriers by embedding accountability and reinforcement into daily routines.
Remote monitoring also enables clinicians to identify patients with declining activity levels earlier, triggering timely intervention before deconditioning becomes established. Centres using integrated digital monitoring systems report faster escalation of care for patients showing warning signs of disease progression or poor adherence. This real-time feedback loop transforms rehabilitation from a time-limited programme into continuous disease management — a model increasingly endorsed by European Society of Cardiology and American Heart Association guidelines for managing chronic cardiac conditions.
What this means
Frequently asked questions
Are smartwatches and fitness trackers proven safe for heart patients?
Yes. Wearable devices are non-invasive and do not deliver therapy; they only measure and record activity. Patients with implanted devices (pacemakers, defibrillators) should confirm model compatibility with manufacturers, but standard commercial wearables are safe. The meta-analysis published in the Journal of the American Heart Association included participants across the spectrum of cardiac diagnoses with no safety concerns reported.
Do digital tools work better than in-person cardiac rehabilitation?
The evidence does not position digital tools as replacements for structured rehabilitation programmes. Instead, apps and wearables enhance traditional rehabilitation by extending monitoring and motivation beyond clinic visits. The most effective approach combines in-person clinical assessment with continuous digital tracking — a hybrid model increasingly recommended by major cardiology societies.
How long do patients need to use these apps to see benefit?
Benefits in activity levels typically emerge within 2–4 weeks of consistent use, according to trial data synthesised in the meta-analysis. However, sustained benefit requires ongoing engagement. Studies show that activity levels decline when app or device use is discontinued, suggesting these tools work best as permanent components of disease management rather than short-term interventions.
As digital health integration accelerates within healthcare systems, cardiac rehabilitation programmes are well-positioned to adopt evidence-backed apps and wearable technologies to improve activity adherence and secondary prevention outcomes. Future research should focus on optimising user engagement strategies, establishing interoperability standards across platforms, and determining cost-effectiveness thresholds for health system implementation in resource-constrained settings. Early evidence from clinical trials and meta-analyses demonstrates that combining digital tools with standard rehabilitation significantly improves long-term outcomes — a finding with direct implications for how cardiac centres structure secondary prevention programmes.
Source: Journal of the American Heart Association meta-analysis
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
